An Oral Cavity Carcinoma Nomogram to Predict Benefit of Adjuvant Radiotherapy Oral Cavity Adjuvant Radiotherapy Prediction Model

Wang SJ, Patel SG, Shah JP, et al. — Thu, 16 May 2013 00:00:00 GMT

Importance

After surgical resection for oral cavity squamous cell carcinoma, adjuvant radiotherapy may be recommended for patients at higher risk for locoregional recurrence, but it can be difficult to predict whether a particular patient will benefit.

Objective

To construct a model to predict which patients with oral cavity squamous cell carcinoma would benefit from adjuvant radiotherapy.

Design and Setting

We constructed several types of survival models using a set of 979 patients with oral cavity squamous cell carcinoma. Covariates were age, sex, tobacco use, stage, grade, margins, and subsite. The best performing model was externally validated on a set of 431 patients.

Participants

The model was based on a set of 979 patients with oral cavity squamous cell carcinoma, including 563 from Memorial Sloan Kettering Cancer Center, New York, New York, and 416 from the Hospital AC Camargo, São Paulo, Brazil. The validation set consisted of 431 patients from Princess Margaret Hospital, Toronto, Ontario, Canada.

Main Outcome and Measure

The primary outcome measure of interest was locoregional recurrence-free survival.

Results

The lognormal model showed the best performance per the Akaike information criterion. An online nomogram was built from this model that estimates locoregional failure-free survival with and without postoperative radiotherapy.

Conclusions and Relevance

A web-based nomogram can be used as a decision aid for adjuvant treatment decisions for patients with oral cavity squamous cell carcinoma.

Association of Ocular and Oculodermal Melanocytosis With the Rate of Uveal Melanoma Metastasis Analysis of 7872 Consecutive Eyes Oculo(dermal) Melanocytosis and Uveal Melanoma

Shields CL, Kaliki S, Livesey M, et al. — Thu, 16 May 2013 00:00:00 GMT

Importance

Ocular/oculodermal (oculo[dermal]) melanocytosis is a congenital periocular pigmentary condition that can lead to the development of uveal melanoma, estimated at 1 in 400 affected patients. In this study, patients with melanocytosis who developed uveal melanoma were found to have double the risk for metastasis compared with those without melanocytosis.

Objective

To determine the relationship of oculo(dermal) melanocytosis to the prognosis of patients with uveal melanoma.

Design, Setting, and Patients

Retrospective chart review of 7872 patients with uveal melanoma treated at the Ocular Oncology Service, Wills Eye Institute, from August 25, 1970, through August 27, 2008.

Exposures

Enucleation, plaque radiotherapy, local resection, or thermotherapy.

Main Outcomes and Measures

Metastasis and death.

Results

Of 7872 patients with uveal melanoma, oculo(dermal) melanocytosis was present in 230 (3%). The melanocytosis involved the sclera (92%), iris (17%), choroid (12%), eyelid (8%), and temporal fossa (1%). Eyes with melanoma and oculo(dermal) melanocytosis had a relative risk for metastasis 1.6 times greater compared with those with no melanocytosis (P < .001). Metastasis of uveal melanoma was 2.8 times higher in patients with iris melanocytosis (P < .001), 2.6 times higher with choroidal melanocytosis (P = .02), and 1.9 times higher with scleral melanocytosis (P < .001). By Kaplan-Meier estimates, metastasis in patients with oculo(dermal) melanocytosis vs no melanocytosis was 2% vs 1.8% at 1 year, 27% vs 15% at 5 years, and 48% vs 24% at 10 years (P < .001). By multivariable analysis, the factors predictive of metastasis in patients harboring uveal melanoma associated with oculo(dermal) melanocytosis were increased tumor thickness (P = .001) and the presence of subretinal fluid (P = .05), and the only factor predictive of death was increased tumor thickness (P = .009).

Conclusions and Relevance

Patients with uveal melanoma associated with oculo(dermal) melanocytosis have double the risk for metastasis compared with those with no melanocytosis. All patients with oculo(dermal) melanocytosis should undergo ophthalmic examination and imaging on a twice-yearly basis because this could help with the early detection of melanoma.

AMA Publishing Group: Oncology Topic Collection

An Oral Cavity Carcinoma Nomogram to Predict Benefit of Adjuvant Radiotherapy Oral Cavity Adjuvant Radiotherapy Prediction Model

Association of Ocular and Oculodermal Melanocytosis With the Rate of Uveal Melanoma Metastasis Analysis of 7872 Consecutive Eyes Oculo(dermal) Melanocytosis and Uveal Melanoma